Saund Saran

CHIEF BUSINESS OFFICEROncotelic Therapeutics, Inc. (OTLC) · full profile →Form 4 · filed Jul 16, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 8, 2021Grant(A)103K$016.5M
Mar 31, 2021Conversion(C)16.4M16.4M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 8, 2021Grant(A)216K$0216K
Mar 31, 2021Conversion(C)16K0

Transaction Codes

A
Grant / award
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-21-017102) within minutes of acceptance. Every field above traces to the original document. Verify it directly: